What Orthofix Medical Inc. told the SEC could break it.

Orthofix depends on a limited number of third-party suppliers — some sole-source — for processing activities, components and raw materials; loss of any, or their inability to supply quality-compliant materials, could disrupt production.

“We depend on a limited number of third-party suppliers for processing activities, components and raw materials and losing any of these suppliers, or their inability to provide us with an adequate supply of materials that meet our quality and other requirements, could harm our business.”

MTF is the single supplier for certain allografts in Orthofix's Biologics portfolio (the MTF relationship is ~30% of Biologics revenue), and Orthofix relies on a small number of AATB-accredited tissue banks for human tissue used as bone-graft substitutes — any disruption to donor access or processing would harm the business.

“Furthermore, we rely on a small number of tissue banks accredited by the AATB for the supply of human tissue, a crucial component of our biologics products that serve as bone graft substitutes.”

Orthofix maintains a $275.0 million secured credit facility with Oxford Finance, collateralized by substantially all of its property and IP, bearing interest of at least 8.75%; failure to repay or comply with covenants would be an event of default.

“On November 7, 2024, the Company, as borrower, and its U.S. subsidiaries entered into a $275.0 million secured credit agreement (the "Credit Agreement") with Oxford Finance LLC, as administrative agent and as collateral agent ("Oxford") and certain lenders party th”

All of Orthofix's U.S. products are subject to extensive FDA regulation under the FDCA and Public Health Services Act (and varying foreign regimes); failure to obtain or maintain clearances, or adverse inspections, could trigger recalls, production interruptions or marketing restrictions.

“Most notably, all of our products sold in the U.S. are subject to the Federal Food, Drug, and Cosmetic Act (the "FDCA") and the Public Health Services Act, as implemented and enforced by the FDA.”